Abstract: Provided herein are methods for the treatment of liver cancer. These methods encompass the administration of a compound comprising a modified oligonucleotide, wherein the modified oligonucleotide is targeted to a miRNA. Also provided herein are compositions for the treatment of liver cancer. Such compositions include compounds comprising a modified oligonucleotide, wherein the modified oligonucleotide is targeted to a miRNA. Certain miRNAs have been identified as overexpressed in liver cancer, such as, for example, hepatocellular carcinoma, and are thus selected for targeting by modified oligonucleotides. Further, certain miRNAs have been identified as overexpressed in hepatocellular carcinoma cells exposed to dioxin, and are thus selected for targeting by modified oligonucleotides. Antisense inhibition of certain of these miRNAs has been found to inhibit cell proliferation and induce apoptosis.

Abstract: The invention relates to a double-stranded compound, preferably an oligoribonucleotide, which down-regulates the expression of one or more cardiovascular-related gene. The invention also relates to a pharmaceutical composition comprising the compound, or a vector capable of expressing the oligoribonucleotide compound, and a pharmaceutically acceptable carrier. The present invention also contemplates a method of treating a patient suffering from a cardiovascular disorder or other diseases comprising administering to the patient the pharmaceutical composition in a therapeutically effective dose so as to thereby treat the patient.

Abstract: The present invention relates to the use of sFRP1 polypeptide in the induction of stem cell proliferation, and to its function in the treatment of depleted cellular populations.

Abstract: This invention provides a method for treating a subject suffering from a disease, wherein the disease is characterized by aberrant cellular proliferation or aberrant cellular differentiation, comprising administering to the subject an antagonist of a polypeptide, wherein the polypeptide has an amino acid sequence as presented in SEQ ID NO:2. This invention also provides the use of a polynucleotide as a probe for identifying undifferentiated embryonic stem cells, wherein the polynucleotide comprises a nucleotide sequence as presented in SEQ ID NO:1. This invention further provides the use of the 76A11 polypeptide in vivo or ex vivo for expansion of adult somatic stem cells. This invention further provides the use of an antibody directed to an epitope presented by the polypeptide comprising the amino acid sequence as presented in SEQ ID NO:2 for detection of cancerous cells or of undifferentiated stem cells.

Abstract: The present invention relates to novel uses of growth factors, particularly colony stimulating factors (CSFs), that stimulate migration and differentiation of stem cells in order to promote and enhance recovery from tissue trauma and ischemic events, including ischemia of the central nervous system, as well as for use in preventing or alleviating chronic degenerative processes, including neuronal degeneration